Board of Directors
Michael H. Carrel has served on the board of Axonics since March 4, 2019.
Mr. Carrel is President and Chief Executive Officer of AtriCure (NASDAQ: ATRC), a medical device company that provides innovative solutions for the treatment of atrial fibrillation (AFib) and related conditions. Since joining AtriCure, the company has significantly invested in groundbreaking clinical trials for the treatment of AFib, left atrial appendage management and pain management; expanded its market presence within Europe and Asia; and grown the global employee base from 200 to over 600 employees. Under his leadership, AtriCure has acquired two companies, Estech and nContact, adding leading ablation technologies to further its market position worldwide. Mr. Carrel also serves on the Board of Medical Device Manufacturers Association (MDMA).
Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company, President and CEO of Zamba Corp., a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug-and-play broadband wireless access systems.
Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania. Mr. Carrel has been the Chairman of the Board of Axonics since 2020.
Mr. Cohen has served as CEO of Axonics and member of the board of directors since co-founding the company in October 2013. Mr. Cohen is an accredited public company director with over 35 years of experience in leading medical device companies and serving as a board member at a number of private and publicly traded life science companies.
From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012. Previously, Mr. Cohen spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth fastest growing company in the U.S. in 2004. Mr. Cohen currently serves as a member of the board of directors of Nyxoah SA (NASDAQ: NYXH), a medical technology company developing a neurostimulation therapy for the treatment of obstructive sleep apnea. He also serves as Chairman of the board of directors of BioVentrix Inc., a privately-held transcatheter ventricular restoration company.
From November 2013 to July 2021, Mr. Cohen served as Chairman of the board of directors at BioLife Solutions (Nasdaq: BLFS), a developer and manufacturer of preservation media for regenerative medicine. He was appointed to the BioLife Solutions board in May 2006. From June 2013 to April 2020, he served as an independent director, chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI). Mr. Cohen also previously served on the boards of two companies that successfully executed an exit transaction in 2017: Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Colorado-based Syncroness, Inc., a privately-held contract engineering firm, sold to ALTEN Group, a multibillion-dollar French engineering services company.
Mr. Demski served as the President and CEO of Globus Medical (NASDAQ: GMED) from August 2017 to April 2022. He previously served as CFO from 2003 to July 2008 and as President, Emerging Technologies. Prior to joining Globus Mr. Demski founded Cornerstone Capital LBO Fund, a boutique leveraged buyout consultancy. Mr. Demski’s experience also includes serving as Vice President for Gilo Ventures, a Silicon Valley-based venture capital fund, and serving as Chief Operating Officer of Rendall and Associates, a telecommunications-focused consulting firm. He also managed regional and international distribution for Domino’s Pizza during the company’s growth in the late 1980s. Previously he was an audit supervisor for Peat, Marwick, Mitchell & Company. Mr. Demski received a B.S. in Business Administration from the University of Michigan and an M.B.A. from Stanford Graduate School of Business.
Robert McNamara has served as Axonics' Audit Committee Chairman since November 2018. He is an accomplished senior executive with demonstrated success in public and privately held companies with global operations in highly competitive industries, including medical device, software and high technology. He has extensive experience in initial public offerings (IPOs), mergers and acquisitions (M&A), operations and financial management at early stage, high growth and mature companies. Mr. McNamara has raised significant capital (more than $500M) in public offerings and private placements, while managing investor relations, international operations and strategic planning. As CFO, he has managed and led three IPOs, six acquisitions/mergers, including two exceeding $1B each, and numerous rounds of venture capital funding. In 2015, he was named Acquisition International Magazine’s Texas Healthcare CFO of the Year. He has been the EVP/CFO of four public medical device companies. He is currently a member of the Board of Directors for Xtant Medical, chairs its Compensation Committee and is a member of its Audit Committee. In addition, he was elected council member and served as mayor of Menlo Park, CA.
Mr. McNamara is a CPA (nonpracticing). He has a B.S. from University of San Francisco and an M.B.A. from University of Pennsylvania’s Wharton School.
Dr. Nancy Snyderman is a renowned surgeon, healthcare systems expert, and corporate director. Dr. Snyderman currently serves on the boards of Alkermes (NASDAQ: ALKS) and Axonics (NASDAQ: AXNX).
She serves as a Scientific Advisor to start-up companies Cadence and Strand Diagnostics. She sits on the boards of the Albright Institute at Wellesley College and the Fair Food Network. Dr. Snyderman is a Kellogg Fellow and Fellow in the American College of Surgeons. Her career includes 15 years working on innovative medical programs and products for General Electric and Johnson & Johnson. She began her corporate career in 2003 at Johnson & Johnson, where she created online medical curricula that J&J marketed to the public. For 10 years, Dr. Snyderman served on the board of General Electric’s Healthymagination, which applied technology solutions to the world’s biggest health challenges.
For more than 30 years Dr. Snyderman was an award-winning Senior Medical Editor at ABC and NBC News. Her skills uniquely span the fields of medicine, science, communication, and global media. Dr. Snyderman spent 25 years as a board-certified, practicing Otolaryngologist-Head and Neck Surgeon at UC San Francisco and the University of Pennsylvania.
With deep expertise on the intersection of medicine, big data and the media, Dr. Snyderman recently served as a Consulting Professor at the Stanford University Center for Innovation in Global Health and is cofounder of the Stanford University-NBC News Global Media Fellowship.
Dr. Snyderman is a New York Times bestselling author and has traveled the globe extensively, lecturing and reporting from some of the world’s most troubled areas. Her reporting has garnered her the industry’s most distinguished honors including Emmy, DuPont, Edward R. Murrow, and Gracie awards.